In cancer, the typical epigenetic patterns are altered, leading to the activation of anti-apoptotic and pro-proliferative genes while silencing TSGs such as CDKN2A (Cyclin-Dependent Kinase Inhibitor 2A) [96]. The gene discussed is CDKN2A; the disease is cancer.